R&D Cell/Gene Therapy Unit


Finvector’s Research and Development department with Gene & Cell Therapy Units is at the forefront for translational research and process development activities in advanced therapies.  To be one of the world leaders and pioneers in the field both departments work together, sharing intellectual property and knowledge whilst searching for new technologies to complement our tool box and innovative projects.  Research is undertaken in collaboration with academic groups based in Finland and internationally whilst working alongside our cGMP manufacturing unit.  This close contact of Finvector´s R&D, GMP manufacturing and quality/regulatory teams guarantees high quality reproducible products for the international market.

Cell Therapy & Gene Therapy Unit

FinVector´s Gene - and Cell Therapy Units laboratories are equipped with cutting edge devices, such as disposable systems for various viral vectors development, cell selection/enrichment, culturing and formulation.  The young, enthusiastic team is dedicated on establishing cell therapy and gene therapy solutions from process- to analytical development.  Cell Therapy & Gene Therapy Units work in close collaboration with international academic research groups and clinicians developing new & innovative products.

Viral vectors

FinVector’s development facilities, matched with the extensive experience of our scientific team, enables us to work with a broad range of viral vectors, especially Adenoviruses (recombinant, oncolytic), Adeno Associated Virus (AAV) and Lentivirus. FinVector has developed several manufacturing processes from small flask scale to commercial scale utilizing either serum free suspension bioreactor approach or controlled and disposable fixed bed bioreactor. Scalable and cost effective large scale purification is based on chromatography and tangential flow filtration. Along the process development, product specific assays are developed during the early stage. FinVector has several areas that are dedicated for viral vector process development suitable for upstream and downstream work. Pilot facility is designed for process scale up activities as a last step towards the GMP.